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Abstract In vivo drug metabolism studies with low concen-
trations of analytes and high matrix burden are challenging. Of
special interest are ‘first-in-man’ studies in early stages of
pharmaceutical development that do not use 14C labeled drug
candidates. Beside conventional MS-fishing techniques which
are biased towards known/expected metabolites and mass
defect filtration procedures, this paper focuses on the untar-
geted/unbiased analysis of drug related compounds in complex
matrices using two orthogonal separation techniques: UPLC
and TWIMS. Standard sample material after oral administra-
tion of a drug compound to rats was investigated by UPLC/
TWIMS in MSE acquisition mode using interlaced collision
energies for the parallel detection of [M+H]+ parent ions and
fragments. Due to the fragmentation after ion mobility separa-
tion in the transfer region of the Synapt G2-triwave device,
[M+H]+ ion species are aligned with their related fragments by
virtue of possessing the same retention time and drift time
profile. Four dimensional data analysis of the continuum raw
data was performed by automated peak picking and alignment
within theMSE viewer software. As result, completely purified
MS- and MS/MS-data of metabolites were extracted from raw
mass data with high matrix burden and were used without
compromise for structure elucidation. This analytical method-
ology is universally applicable for the unbiased/untargeted and
robust analysis of any analyte of interest in complex matrices,
including small molecules, peptides and proteins. The high
quality data files can be used as data repositories for the
purpose of retrospective analysis which is of particular interest
for the long term process in drug development.
Keywords Drugmetabolism . Complex sample material .
Ion mobility separation . 4D-data analysis . Data repository .
MSE-analysis
Introduction
Drug metabolism studies are challenging. This is especially
true for the screening for drug related compounds in com-
plex samples of in vivo studies with high matrix burden
including the routinely used samples of plasma, urine, bile,
and faeces, but also of whole blood and of extracts of
organs.
Depending on applied drug doses and the pharmacoki-
netics of the analytes, signals of interest with exceptionally
low intensity need to be screened out of matrix interferences
of endogenous and/or co-administered additives with high
signal intensity. Additionally the absence of radiotracers,
which is the case in ‘first-in-man’ studies, results in chal-
lenging situations when metabolites needed to be reliably
identified and elucidated in early stages of pharmaceutical
development. With the background of regulatory guidelines
[1, 2] and the continuous progress of analytical technologies
the pivotal role of 14C-metabolism studies was recently
revisited with the proposal that regulatory requirements
can be even better met without conducting the traditional
animal radiolabelled studies [3]. However the discussion
evolves, it underlines the increasing importance of reliable
high sensitivity screening methodologies in ‘real life sam-
ples’, especially in cold in vivo samples, for the future drug
development process.
Many analytical approaches using different mass spec-
trometry techniques have been developed for the screening
and identification of drug related compounds in drug me-
tabolism studies. Unit resolution platforms like triple
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quadrupole [4] or ion trap instruments [5–8] used targeted
approaches which required multiple runs of samples or
predicted MRM- or untargeted enhanced survey scans to
trigger product ion scanning within one analytical run. The
data were successfully used for both metabolite identifica-
tion and quantification of the parent drug and semi quanti-
fication of metabolites of in vivo and in vitro studies.
The high resolution hybrid systems, such as the LTQ-
Orbitrap have effectively demonstrated their capabilities for
parallel data collection, mass defect filtration and exact mass
ion extraction for both in vitro and in vivo drug metabolism
studies with and without data/information dependent acqui-
sition methodologies [9–22]. With sophisticated generic
settings including peak intensity dependent triggering and
inclusion/exclusion list dependent triggering of MS/MS or
MSn experiments, in vivo drug metabolism studies were
performed with high reliability with respect to metabolite
coverage.
The MSE acquisition technique represents another ap-
proach and provides a completely untargeted and unbiased
methodology which can be used with fast acquisition hybrid
quadrupole time-of-flight (QTOF) instruments in combination
with the separation power of ultra high performance liquid
chromatography (UPLC). The advantage of this technique is
the simplified data collection which is (1) independent of
exclusion lists for high abundant matrix interferences that
may impair the efficiency of data dependent MS/MS-triggering
and which is (2) independent of generic or predictive inclusion
lists which are biased and therefore potentially not comprehen-
sive. MSE data enable the analysis for any compound of inter-
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Fig. 1 Metabolism pathways of M0
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This technology was previously shown to be universally
applicable not only for drug metabolism studies [23–26], but
also for impurity analysis [27], environmental/waste water
analysis [28, 29], and proteomics [30]. We here report the
use of the UPLC-QTOF/MSE approach as general ‘first-line’
screening for in vitro and in vivo studies. Published drug
metabolism data of the recently approved drugs Dabigatran
[31] and Linagliptin [32] were based on this technology. For
both drugs the alignment of parent-ions with fragment ion
species were achieved by matching the extracted ion chroma-
tograms (XICs) with exactly the same peak shape. The
chromatographic resolution therefore is an important factor
in the process. TheMSE approach perfectly works for samples
with clean matrix from in vitro studies and with in vivo
samples with advantageous analyte/matrix ratio. However,
for the identification of low level metabolites dedicated
MS/MS-experiments are needed due to strong interferences
of co eluting matrix ions.
The utilization of ion mobility separation (IMS), as an
additional principle of differentiation, will play a key role for
the further development of the MSE acquisition methodology.
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Fig. 4 Identification of drug
related compound in rat urine
by correlation of XICs
of the diagnostic fragment
[M-THP+H]+ with metabolite
[M+H]+-ions. Upper trace: data
‘high’: XIC of
[M-THP+H]+, light gray:
TIC. Lower traces: data ‘low’:
XIC of parent drug and
metabolite’s [M+H]+,
light gray: TIC
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are separated by differences of individual size to charge ratios
in combination with the interaction of a buffer gas. The ion
mobility separation of structural isomers, polymeric conform-
ers and enantiomers in applications of proteomics, glycomics
and metabolomics was successfully demonstrated with vari-
ous instrumental setups [33–35].
In this publication we present the combination of UPLC
and travelling wave ion mobility separation (TWIMS) to-
gether with the MSE acquisition methodology as new ap-
proach for the reliable, unbiased and fast analysis of drugs
and its metabolites which is tailored for the analysis in
complex biological sample material.
Only parts of the parent compound structure and only
reduced mass spectrometry data are allowed to be presented.
However, this does not detract from the demonstration of the
viability and utility of the general approach outlined here.
Materials and methods
Chemicals and reagents
The drug compound of interest (M0) was synthesized by the
medicinal chemistry group of Boehringer Ingelheim Pharma
GmbH & Co. KG, Ingelheim, Germany. Chemical purity
was >97 %. For lock mass correction a solution of leucin
enkephalin (Sigma Aldrich, Stadt, Germany) at a concentra-
tion of 2 μg/ml in acetonitrile/0.1 % aqueous formic acid
(1:1) was used. Acetonitrile, methanol, water and formic
acid were of analytical grade or higher purity and were
obtained from Sigma Aldrich (Steinheim, Germany).
Biological sample material
The study protocol of in vivo experiments was in full
conformance with the respective animal experimentation
application approved by the local animal welfare officer of
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach,
Germany, as well as by the responsible supervisory author-
ity, Tübingen, Germany. Boehringer Ingelheim Pharma
GmbH & Co. KG is accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International (AAALAC).
Male and female rats (n03, stain: Crl:WI(HAN)) received
a single oral dose of 50 mg/kg of the drug compound dis-
solved in water after an overnight fast (≥10 h). Plasma
(sampling times: 0, 0.25, 0.5, 1, 6, 24 h), urine and faeces
(fractions 0–48 h) were sampled. Bile fractions (0–6 h) were
obtained from bile duct cannulated rats (n02). Sample ali-
quots of urine and faeces samples of individuals were pooled
proportionally according to the relative weight of individual
sample fractions. Plasma was pooled proportionally to sam-
pling times to yield a sample in which concentrations of
analytes were proportional to AUC’s (AUC 0 area under
the concentration time curve) within the given time interval
[36, 37]. The pooled plasma (0–24 h) was processed by solid
phase extraction using OASIS HLB cartridges (200 mg, 6 cc,
Waters, Milford, MA, USA) and 0.1 % aqueous formic acid/
acetonitrile (1:9) as eluent. Pooled faeces samples were
exhaustively extracted with acetonitrile/water (1:1). Pooled
urine and bile was diluted 1:10 with aqueous formic acid
(0.1 %) before analysis. All samples and sample extracts
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Fig. 5 Urine after
administration of M0. Upper
trace: data ‘high’: XIC of
[M-THP+H]+, light gray: TIC.
Lower traces: data ‘low’: XIC
of parent drug’s and PEG’s
[M+H]+, light gray: TIC,
Inserted figure: mass data
at rt017.9 min, data ‘low’
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UPLC/TWIMS/MSE QTOF mass spectrometry
Metabolite profiles of the sample material were analyzed by
ultra high performance liquid chromatography coupled to
traveling wave ion mobility separation QTOF mass spectrom-
etry using the MSE acquisition methodology. Volumes of 5 μl
of sample material were injected on column. The UPLC-
system (Acquity UPLC, Sample Manager 2777, Binary sol-
vent manager, Column Heater/Cooler, all Waters, Milford,
MA, USA) was coupled to a Synapt G2 mass spectrometer
(Waters MS Technologies, Manchester, UK). Samples were
analyzed by reverse phase UPLC using 150×3.0 mm columns
(Ascentis express Phenyl-Hexyl, 2.7 μm, Supelco, USA) with
a gradient of aqueous ammonium formate (0.05 M, pH 8) as
eluent A versus acetonitrile/methanol (1:1) as eluent B with a
flow rate of 0.6 ml/min (gradient: 5 % B at 0 min, 5 % B at
1min, 30%B at 20min, 99%B at 23min, 99%B at 32min).
The column temperature was 40 °C.
The combined Z-spray/lockspray interface of the Synapt
G2 [38, 39] was operated in positive ion mode with nitrogen
as cone and desolvation gas at flow rates of 20 L/h and
1,000 L/h, respectively. The source temperature and desol-
vation temperature were set to 120 °C and 550 °C, respec-
tively. The capillary, sampling cone and extraction cone
voltages were set to 3.0 kV, 20 V and 4 V, respectively.
The first quadrupole operated in non-resolving RF-only
mode. The collision energy of the trap cell was set to 4 eV.
Mass spectral data over the range m/z 50–1200 were ac-
quired in two separate channels using two continuously
interlaced collision energies of the transfer cell, at 0 eV
and 25 eV, with a switching frequency of 2 Hz. The trap,
IMS and transfer traveling wave devices were operated with
traveling wave amplitudes and velocities of 8.0 V and
508 m/s, 40.0 V and 1000 m/s, and 3.0 V and 450 m/s,
respectively. The trap/transfer cells were operated with ar-
gon at a pressure of 2.5 e-2 mbar. Nitrogen as drift gas was
introduced into the IMS cell to maintain a pressure of
3.1 mbar. The time of flight analyzer was operated using
V-mode optics with an average mass resolution of m/Δm0
20,000 (full-width at half-maximum definition). The TOF-
pusher and trap-gate frequencies were 18.5 kHz and
92.5 Hz, respectively. Thus, individual IMS cycles of
10.8 ms duration were analyzed with a pusher period of
54 μs resulting in 200 TOF pushes/IMS cycle. Mass data
were lock mass calibrated with leucine-enkephalin (m/z
556.2771). The calibrant was introduced with a flow rate
of 10 μl/min and was measured for 0.5 s with a frequency of
1/min over the full chromatographic run time. Lock mass
data were acquired in a third separate channel. Data acquisi-
tion and processing were performed using Masslynx (V4.1,
SCN714), Driftscope (V2.1) and MSE viewer (V1.2).
Results and discussion
Pooled samples of plasma, urine, bile and faeces after oral
administration of a drug compound to rats were investigated
in this study. Native urine and bile were diluted; plasma and
faeces were extracted before analysis.
The investigated compound (M0), a tetrahydropyranyl
(THP) derivative with substituted heteroaromatic system,
was subject to extensive phase I metabolism (Fig. 1). Metab-
olites were formed by initial oxidation of the THP-moiety in
2-, 3- and 4-position (metabolite fraction M8). Two major
metabolites, the ring-open carboxylic acid/alcohol (M1) and
the diol (M2), were formed by initial oxidation in 2-position
of the THP-moiety followed by further oxidation (leading to
M1) or reduction (M2), respectively. Adducts with urea
were identified in urine (M3, M4). Minor metabolites were
CE = 0 eV
Data ‘Low’
-> Parent Ions
CE = 0 eV
Data ‘Low’
-> Parent Ions























XIC D: m/z 564.3615
XIC C: [M0+H]+
Fig. 6 Urine after administration of M0. Mass data ‘high’ and
‘low’ at rt017.9 min ±1.5 s, plotted versus the drift time. Upper
2 traces: data ‘high’: XIC of [M-THP+H]+, and PEG fragment,
light gray: TIC Lower 2 traces: data ‘low’: XIC of parent drug’s
and PEG’s [M+H]+, light gray: TIC
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formed by oxidation of the heteroaromatic system (M5, M6,
M7). Phase II transformations played a subordinate role.
Basic principles of metabolite screening
by UPLC/TWIMS/MSE QTOF-MS
In general, samples were analyzed for drug related com-
pounds by two independent, orthogonal separation techni-
ques including UPLC (ultra high performance liquid
chromatography) and TWIMS (travelling wave ion mobility
separation) followed by detection with high resolution
QTOF mass spectrometry using the MSE acquisition ap-
proach. The instrument was operated in positive ion mode
with the first quadrupole operating non-resolving, in RF-
only mode.
The triwave geometry of the instruments ion mobility cell
[38, 39] allows fragmentation in both the trap (pre IMS sepa-
ration) and the transfer regions (post IMS separation). In this
application, transfer fragmentation was performed. According
to the MSE acquisition methodology the collision energy was
alternately switched with a frequency of 2 Hz between two
settings ‘low (00 eV)’ and ‘high (025 eV)’ which allowed the
parallel detection of [M+H]+-ions with only minimal fragmen-
tation and of only fragment ions, respectively (Fig. 2). [M
+H]+-ions and fragments of all, endogenous compounds and
drug related compounds of interest, were acquired in two
separated data sets ‘low’ and ‘high’, respectively. Ions from
an individual compound e.g. [M+H]+-ions in the data ‘low’
and their specific fragments in the data ‘high’, are aligned by
the retention time (retention time alignment).
In combination with ion mobility separation, [M+H]+-
ions from the RF-only quadrupole are first collected in the
trap cell of the instruments triwave device and then period-
ically released in packages into the IMS cell (Fig. 2). After
separation due to differences in collisional cross sections,
they are transported into the transfer cell. Here, with inter-
laced collision energies, the [M+H]+-ions were either trans-
ported with a low collision energy (0 eV) without or
minimum fragmentation to the TOF detector or subjected
to additional fragmentation with a higher collision energy
(25 eV). With collision energy applied after ion mobility
separation, fragments retain the original drift time of the
parent ions. As a result, all ions of an individual compound
e.g. [M+H]+, and its fragments are aligned not only by
retention time, but additionally by drift time (0retention time
and drift time alignment).
In summary, all ion species of the two data sets ‘high’
(product ions) and ‘low’ (parent ions) were characterized by
the four dimensions intensity (I), mass (m/z), retention time
(rt) and drift time (dt). Ions of individual compounds are
aligned by specific combinations of retention- and drift
times.
Data evaluation, basic principles
The general concept of screening for metabolites by diag-
nostic drug related fragments by rt/dt-aligned MSE data is
discussed in the following:
The basis for the metabolite screening with the MSE
methodology is a sound understanding of the fragmentation
pathways of the parent drug’s [M+H]+. Drug related com-
pounds can be identified by extracted ion chromatograms
(XICs) of diagnostic fragments in the high collision energy
data (‘data high’) which are specific for defined substructures
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Fig. 7 Urine after
administration of M0. Mass
data at rt017.9 min before and
after mobility separation
(rt/dt-windows: 1.5 s/1.5 ms).
Left: MS-spectra of data ‘low’,
drift time separation of
[M+H]+-parent ions at 4.4 and
7.6 ms. Right: MS/MS-spectra
of data ‘high’, remaining
[M+H]+- and fragment ions
with conserved drift time sepa-
ration of [M+H]+ parent ions
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of the parent compound. Associated [M+H]+-ions are identi-
fied with their XICs in the low collision energy data (‘data
low’) by correlation with exactly matching retention times and
chromatographic profiles and drift times and vice versa. Inde-
pendent of the intensity, any known fragment or — with
respect to putative biotransformations — any expected prod-
uct ion can be used for this approach. This methodology is
presented in the following sections.
The product ion spectrum of the parent drug’s [M+H]+,
M0, is shown in Fig. 3. The base ion was formed by loss of
the THP-residue, [M-THP+H]+, and was used as diagnostic
fragment for metabolites with unchanged heterocyclic moi-
ety. In Fig. 4 the search for metabolites with [M-THP+H]+
in urine is presented. The extracted ion chromatogram of
[M-THP+H]+ in the data ‘high’ is displayed in the upper
trace (Fig. 4, XIC A). The chromatograms below show the
XICs of the correlated [M+H]+-ions of the parent compound
M0 (XIC B) and the metabolites M1 (XIC C: M0+2O), M2
(XIC D: M0+O+2H), M3, M4 (XIC E: M0+CH2N2O) and
M8 (XIC F: M0+O) in the data ‘low’. Metabolite specific
ions of both data ‘high’ and ‘low’ exhibit exactly the same
peak shape. The higher the chromatographic resolution, the
better the alignment of metabolite related peaks and the
discrimination of matrix signals.
With sample material of in vivo studies a complete
separation of interferences is only achieved in rare cases
due to the high matrix burden. Thus, the unambiguous
structure assignment based on only retention time aligned
‘high’ and ‘low’ data alone is challenging, sometimes
impossible. With the introduction of the additional di-
mension of separation by ion mobility, completely puri-
fied MS- and MS/MS data are achievable. In Fig. 5 a
common situation of a strong interference with matrix
compounds with nearly identical chromatographic profile
to the compound of interest is shown. The parent com-
pound, M0, co eluted with a polyethylenglycol isomer,
[M+H]+ m/z 564, at the retention time of 17.9 min. The
IMS data can be used to unambiguously resolve these
dt = 0-10 ms 
Drug related:Matrix:
dt = 3.9 ms 
dt = 6.9 ms 
dt = 3.2 ms 










Fig. 8 Urine after
administration of M0. Mass
data ‘low’ at retention time of
metabolite fraction M8
at rt014.0 min±1.5 s. Upper
spectrum: Mass data over all
drift times: 0–10 ms. Lower
spectra: Mass data of
metabolite ions and prominent
matrix signals at defined drift
time windows (±1.5 ms)
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peaks and align their fragments without the need for
dedicated MS/MS investigations. Figure 6 shows the
XIC data ‘high’ (2 upper traces) and ‘low’ (2 lower
traces) of the peak top at 17.9 min (average, ±1.5 s)
which is now plotted versus the drift time dimension.
Again, the XIC of the diagnostic fragment, [M0-THP+H]+
(XIC A) can be used as indicator for the drug related
compounds. The drift time for this fragment was 4.4 ms.
The aligned [M+H]+ of the parent compound was unambig-
uously identified by the corresponding XIC in the data ‘low’
(XIC C). The [M+H]+ of the PEG-isomer, separated by
IMS was detected with a drift time of 7.6 ms (XIC D).
Its fragment C6H13O3
+, m/z 133, which, in a similar
manner, can be used as general diagnostic fragment for
PEG-isomers (see below) co eluted with the same drift
time at 7.6 ms (XIC B).
Figure 7 demonstrates the improvement of the data
quality of MS- (data ‘low’, left) and MS/MS-spectra
(data ‘high’, right) from rt-aligned data to combined rt/
dt-aligned data. The [M+H]+-ion species of the parent
drug and the PEG-isomer were separated from one
another and were additionally completely stripped of
other interferences by applying appropriate retention
time and drift time windows of ±1.5 s and ±1.5 ms,
respectively. Due to the conservation of the [M+H]+-
parent ion drift times, the parent compound- and PEG-
fragments were also completely separated and cleaned
from one another and clear of other matrix interferents.
Thus, the combined rt/dt-aligned MS- and MS/MS-spec-
tra can directly be used for structure elucidation without
compromise.
A second representative met-ID example is presented
using the metabolite fraction M8 which consisted of oxida-
tion products of the THP moiety. The XIC of the [M+H]+
showed a broad peak at 14.0 min (see Fig. 4, XIC F). In
Fig. 8, the mass spectra of the data ‘low’ of the peak top at
14.0 min (±1.5 s) without and with ion mobility separation
is presented: Without IMS the [M+H]+ together with its in
source fragment [M-THP+H]+ were present with high abun-
dant interferences of co eluting matrix compounds (upper
spectrum). The ions were separated and aligned by IMS into
drug related ions (dt03.2 ms and 4.5 ms) and matrix signals
(dt03.9 ms and 6.9 ms). The spectra are shown with rt/dt-
windows of ±1.5 s/±1.5 ms. The process of ion alignment is
demonstrated again in Fig. 9: Here the ‘high’ and ‘low’
mass data of the peak top at 14.0 min (±1.5 s) are plotted
versus the drift time; XICs which significantly contribut-
ed to the total ion current are selected. The XIC of the
diagnostic fragment, [M-THP+H]+ of the data ‘high’
showed two peaks at the drift times 3.2 ms and 4.5 ms
(upper trace, XIC A). In the data ‘low’ the XIC of the
M8’s [M+H]+ (at 4.5 ms, XIC B) could be unambigu-
ously aligned with the diagnostic fragment of the data
‘high’. In this example, the second peak at 3.2 ms (XIC
C) corresponded to the XIC of the [M-THP+H]+ itself,
which was formed by in-source fragmentation and there-
fore resolved in the IMS cell from the parent ion prior to the
transfer cell fragmentation process. The prominent matrix ions
were completely separated with drift times of 3.9 ms and
6.9 ms, respectively (XIC D and E).
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Drif t time [ms]1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0
100%
XIC D: m/z 285.0804
(Matrix)
XIC E: m/z 475.2249
(Matrix)
M8
Fig. 9 Urine after administration of M0. M8-data ‘high’ and ‘low’ at
rt014.0 min±1.5 s, plotted versus the drift time. Upper trace: data
‘high’: XIC of the diagnostic [M-THP+H]+-ion, light gray: TIC Lower
traces: data ‘low’: XICs of the [M+H]+-ion of M8 and its in-source
fragment [M-THP+H]+ together with XICs of additional matrix signals
with significant contribution to the TIC, light gray: TIC
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Data evaluation, implementation of automated data mining
tools
The general approach of the data evaluation process as dis-
cussed in the previous section is laborious and time consuming.
For an accelerated routine analysis of the 4D ‘high’ and ‘low’
data the MSE viewer was used as an automated software tool.
In a first step of data processing, the included apex convolution
algorithm reduced the raw data, i.e. the continuum data with















Fig. 10 4D Apex convolution principle: Left picture: continuum 4D
raw data which is defined by intensity (I), mass (m/z), retention time
(rt), and drift time (dt). Mid picture: continuum data is convoluted to
discrete components. Right picture: display of convoluted data in the
m/z-/rt-/dt-data space: signals are separated when differentiated in at
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Fig. 11 Identification of drug
related compound in rat faeces
after 4D apex convolution
of ‘high’ and ‘low’ data:
rt/dt-alignment of component
signals (rt/dt-windows: ±1.5
s/±0.05 ms). Upper trace:
[M-THP+H]+ component peaks
versus retention time. Lower
traces: parent drug’s and
metabolite’s [M+H]+
component peaks after rt/dt-
alignment versus retention time
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drift time (dt), to single discrete component data (Fig. 10).
Consequently, a particular ion of interest can be displayed as
a single data point in a 3 dimensional data space which is
defined by the axes m/z, rt, and dt. In this 3D data space,
signals are resolved which are differentiated in at least one of
the parameter m/z, rt or dt. The fourth dimension which is the
intensity (I) is not displayed in Fig. 10. In the second step of
data processing, the MSE viewer allows the extraction of puri-
fied MS- and MS/MS data by appropriate settings of retention
time and drift time windows. The drift time is implemented as a
filter and the display can be toggled to show the data with and
without dt-separation.
With regard to the worst case of in vivo met-ID studies,
the very low abundance metabolite signals are resolved in
m/z





















Fig. 12 Metabolite M1 in
faeces (rt: 7.06 min), Data
‘low’: a continuum data, b
after apex convolution and rt/dt-
alignment (rt: 18.147±1.5 s, dt:
4.38±0.05 ms). Data ‘high’:
c continuum data, d after apex
convolution and rt/dt-alignment
(rt: 18.147±1.5 s, dt:
4.38±0.05 ms)
m/z























Fig. 13 Metabolite M6 in
faeces (rt: 12.16 min), Data
‘low’: a continuum data, b after
apex convolution and rt/dt-
alignment (rt: 18.147±1.5 s,
dt: 4.38±0.05 ms). Data ‘high’:
c continuum data, d after apex
convolution and rt/dt-alignment
(rt: 18.147±1.5 s, dt:
4.38±0.05 ms)
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the 3D-data space (m/z vs. rt vs. dt) and can be identified as
drug related signals, even in the presence of very intense co
eluting matrix ions.
The above process is demonstrated in the following, using
a common challenging, in vivo met-ID example: the analysis
of an extract of rat faeces with low concentrations of drug
related compounds together with very high matrix burden.
The continuum raw data ‘high’ and ‘low’ were converted
to discrete component data by the peak detection software
for further metabolite analysis. In Fig. 11 the screening for
drug related compounds in the faeces sample with the diag-
nostic [M-THP+H]+ fragment is presented: The upper trace
shows the ‘XIC’ of the [M-THP+H]+ of the peak detected
component data ‘high’. The lower traces shows the auto-
matically rt/dt-aligned [M+H]+-ions of the parent drug (M0)
and the metabolites M1, M2, M5 and M6 of the peak
detected component data ‘low’. Due to the orthogonality
of UPLC and TWIMS, interfering ions of unwanted matrix
are efficiently discriminated. The spectra are shown with rt-
and dt-windows of ±1.5 s and ±0.05 ms, respectively.
In the Figs. 12 and 13 the comparison of continuum raw
data at the peak tops of the [M+H]+-XICs of the metabolites
M1 and M6 versus the rt/dt-aligned MS data is presented.
The continuum ‘high’ and ‘low’ raw data (Figs. 12 and 13,
left) demonstrate the analytical challenge with low abundant
analyte signals and high matrix interferences which is a
common situation with in vivo sample material, especially
in samples of faeces or bile. After apex convolution in
combination with rt/dt-alignment the MS- and MS/MS-
spectra (Figs. 12 and 13, right) were completely purified
from all matrix signals. The extracted data were identical to
directed MS/MS-spectra of selected [M+H]+-parent ions
and can be used without compromises for structure elucida-
tion and further downstream processes. The advantage over
directed analytical approaches is the simplified setup which
is completely unbiased: Without compromise, rt/dt-aligned
MS- and MS/MS-data from any compound of interest can
be extracted retrospectively at any time. The shown
examples of the metabolites M1 and M6 are representative
for all analytes including M0, M2, M3, M5. The rt/dt-
alignment resulted to cleaned MS- and MS/MS spectra (data
not shown here).
To further demonstrate the universality of this approach
an excursus to the analysis of the PEG-isomers is presented.
As discussed earlier the parent compound co eluted with a
PEG-isomer with nearly the same retention time at 17.9 min
(Fig. 5). Figure 7 showed the alignment of the [M+H]+, m/z
564 (data ‘low’), of the PEG-isomer with m/z 133.0865
(C6H13O3
+) of the data ‘high’, which is a common fragment
of this compound class [40]. This general PEG-related frag-
ment can be used as diagnostic ion for PEG-isomers in the
original data ‘high’ and ‘low’ for the identification of all
PEG-isomers which were present in the urine sample
(Fig. 14): The XIC of m/z 133.0865 is shown in the upper
trace; a superimposition of aligned [M+H]+-XICs of the
PEG-isomers was correlated in the lower trace. Data pro-
cessing with the MSE viewer by apex convolution and rt/dt-
alignment resulted also for this PEG-isomers to completely
purified MS- and MS/MS-data for further structure elucida-
tion/assignment (data not presented).
Summary and conclusions
This new approach for the screening and elucidation of
drugs and their metabolites in complex matrix consists of
the combination of two orthogonal separation techniques,
UPLC (ultra high performance liquid chromatography) and
TWIMS (traveling wave ion mobility separation), together
with high resolution QTOF mass spectrometry using the
MSE acquisition methodology. Two mass data sets were
acquired separately in two channels using interlaced colli-
sion energies detecting [M+H]+ parent ions and product ions
in parallel. All ion species of the two data sets were charac-
terized by the four dimensions intensity (I), mass (m/z),
retention time (rt) and drift time (dt). The raw data were
Retention Time [min]
100%




CE = 0 eV
Data ‘Low’
-> Parent Ions










XIC of  m/z 133.0865
Fig. 14 Urine after
administration of M0.
Data ‘high’and ‘low’. Upper
trace: data ‘high’: XIC
of PEG fragment, m/z 133,
light gray: TIC. Lower trace:
data ‘low’: superimposition
XICs of PEG-isomers
[M+H]+, light gray: TIC
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processed by the apex convolution software for the reduc-
tion of the continuum m/z-, rt- and dt-data to discrete com-
ponents. As a result, ions that differ in at least one of the
dimensions m/z, rt or dt were resolved. Using fragmentation
after ion mobility separation, [M+H]+ ion species of the low
collision energy channel are aligned with their related frag-
ments of the high collision energy channel by virtue of
possessing the same combination of retention time and drift
time. Thus, associated MS- and MS/MS-data for com-
pounds of interest are extractable with appropriate rt- and
dt-windows. Due to the orthogonality of UPLC and
TWIMS, unwanted interfering ions, e.g. high intensity ma-
trix signals which are generally common in mass data of in
vivo sample material, were efficiently discriminated. As
result, completely purified MS- and MS/MS-data for any
compounds can be extracted from the mass data for further
evaluation. This principle supersedes the data dependent
scan methodologies which are laborious and difficult to set
up in complex sample materials with low concentrations of
analytes and high matrix burden. The MSE viewer as a
tailored software tool was used for automated data mining.
This contribution refers to the application of UPLC/
TWIMS/MSE QTOF Mass Spectrometry to drug metabo-
lism studies. Its general and universal applicability is dem-
onstrated by the analysis of in vivo sample material of
especially faeces containing highest concentrations of ma-
trix components and low concentrations of analytes. The
MS- and MS/MS data of drug related compounds was
completely purified from matrix signals and could be used
for further processing, e.g. structure elucidation/structure
assignment, without compromise.
In general the unbiased ‘high/low’ 4D data sets open the
field for retrospective analysis of any compound at any time
including drug metabolites, up and down regulated endog-
enous compounds, small molecules and proteins without the
need for sample reanalysis which is always questionable
with respect to stability and storage conditions. Thus, the
4D data sets can be used as comprehensive data repositories
during the development process of a drug including early in
vitro investigations, first in man trials, drug metabolism
studies in samples of toxicology species and late stage 14C
human ADME trials. This generic approach is particularly
useful in cases where the coverage of human metabolites
need to be retrospectively demonstrated in previously ana-
lyzed preclinical samples of toxicology testing.
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